CSTL (Castle Biosciences) GF Value Rank: 8 (As of Jul. 11, 2026) — 100% Above Median


CSTL Castle Biosciences Inc CSTL
77 GF Score
Price $23.72
GF Value $29.20
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Castle Biosciences GF Value Rank?

Castle Biosciences CSTL -3.42% 77 GF Value Rank is 8 as of Jul. 11, 2026, which is 100% above its 10-year median of 4.00. GuruFocus rates CSTL with a GF Score™ of 77/100 and a GF Value™ of $29.20 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Castle Biosciences has the GF Value Rank of 8.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


Castle Biosciences GF Value Rank Related Terms


CSTL vs FLGT, MYGN, OPK: GF Value Rank Comparison

For the Diagnostics & Research subindustry, Castle Biosciences's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Castle Biosciences GF Value Rank vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Castle Biosciences's GF Value Rank distribution charts can be found below:

* The bar in red indicates where Castle Biosciences's GF Value Rank falls into.


CSTL
77GF Score
Castle Biosciences Inc CSTL
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 8 mean?
Castle Biosciences (CSTL) has a GF Value Rank of 8 as of Jul. 11, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Castle Biosciences and its competitors. This is 100% above median its historical median of 4.00. Over the past decade, Castle Biosciences' GF Value Rank has ranged from 2.00 to 10.00.
Is Castle Biosciences' GF Value Rank too high?
Castle Biosciences' current GF Value Rank of 8 is 100% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 2.00 to a high of 10.00. Overall, Castle Biosciences has a GF Score™ of 77/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Castle Biosciences' GF Value Rank compare to FLGT and MYGN?
Castle Biosciences' GF Value Rank of 8 can be compared against companies in the Medical Diagnostics & Research industry. Historically, Castle Biosciences' own GF Value Rank has ranged from 2.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Medical Diagnostics & Research company?
A good GF Value Rank depends on the Medical Diagnostics & Research industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on Castle Biosciences and its competitors. Castle Biosciences's current GF Value Rank is 8, which is 100% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Castle Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Castle Biosciences (CSTL) is currently considered Modestly Undervalued. The stock's GF Value™ is $29.20, compared to a current price of $23.72 — trading 18.8% below its estimated fair value. The current GF Value Rank is 8, which is 100% above median its 10-year median of 4.00. Castle Biosciences' overall GF Score™ is 77/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For Castle Biosciences (CSTL), the current GF Value Rank is 8 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Castle Biosciences (CSTL) Overvalued in 2026?

Based on GuruFocus' analysis, Castle Biosciences stock appears to be undervalued. The current stock price of $23.72 is trading 18.8% below its estimated GF Value™ of $29.20. GuruFocus considers Castle Biosciences to be Modestly Undervalued.

Key valuation signals for CSTL:

  • GF Value Rank: 8 (100% above median its 10-year median of 4.00)
  • GF Value™: $29.20 vs. price of $23.72 (18.8% below fair value)
  • GF Score™: 77/100 with 4 warning signs

No single metric tells the full story. See the CSTL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Castle Biosciences Business Description

Other Exchanges 086:Germany
Address 1500 West Parkwood Avenue, Suite 401, Friendswood, TX, USA, 77546
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
77GF Score

Get the complete analysis for CSTL

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.72
Price
$29.20
GF Value